Falk Ehmann is Head of the Innovation and Development Accelerator workstream (TRS-INO) at the European Medicines Agency (EMA). His main responsibilities include co-chairing the EU Innovation Network promoting Innovation and novel methodologies in drug development with focus in the areas of Pharmacogenomics (Clinical Pharmacology), Nanomedicines, Combination Medicinal Products, and other -omics in connection with Personalized Medicine. As part of engagement in Pharmacoeconomics, Health Care Market Place and Early Drug Development with King’s College Falk created a cost-benefit decision model, designed protocols for First in Man clinical studies and proposed a definition for Innovation in Health Care in order to value it, which has been shared with the National Institute for Health and Care Excellence (NICE) and the UK ministry of Health. Prior to joining the EMA Dr Ehmann studied European and International law at the University Berlin, worked as Public Health Researcher at the Robert Koch Institute and at different University Hospitals. Falk Ehmann wrote his PhD thesis on Molecular Cell Signalling at the Institute of Biochemistry and Molecular Biology at the University Hamburg. His Master Thesis discusses coping mechanisms and responses of European Health Care Systems to Influenza Pandemic. Falk published more than 30 articles in peer reviewed Journals.